pharma · Non-muscle invasive bladder cancer (NMIBC) · Low Grade Upper Tract Urothelial Carcinoma · TYRA
Tyra Biosciences
Tyra Biosciences clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Carlsbad, USA
- Employees
- 93
- Programs
- 9
- Drugs
- 3
- Patents
- 17
Tyra Biosciences projects
9 ClinicalTrials.gov programs sponsored by Tyra Biosciences.
Tyra Biosciences has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Dabogratinib (TYRA-300) 60mg
Tyra Biosciences
Low Grade Upper Tract Urothelial Carcinoma
1 trial -
TYR300-101
Tyra Biosciences
Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
1 trial -
TYR300-202
Tyra Biosciences
Non-muscle invasive bladder cancer (NMIBC)
1 trial -
TYRA-300
Tyra Biosciences
Locally Advanced Urothelial Carcinoma
1 trial -
TYRA-300 0.125 mg/kg
Tyra Biosciences
Achondroplasia
1 trial -
TYRA-300 60mg
Tyra Biosciences
Low-grade NMIBC
1 trial -
TYR200-101
Tyra Biosciences
Locally Advanced Cholangiocarcinoma
1 trial -
TYRA-300-B01
Tyra Biosciences
Healthy
1 trial -
TYRA-430
Tyra Biosciences
Metastatic Hepatocellular Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Tyra Biosciences have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.